Ergomed (ERGO)

 

ERGO Share PerformanceMore

52 week high171.40 12/04/16
52 week low117.00 16/09/16
52 week change -7.00 (-4.14%)
4 week volume446,252 21/12/16

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Ergomed CFO and general counsel granted options

Ergomed founder and chief executive Dr Miroslav Reljanovic has granted options over 100,000 ordinary shares from his p...

Award of Options by CEO to CFO and General Counsel

RNS Number: 5759Q Ergomed plc 30 November 2016 PRESS RELEASE FOR IMMEDIATE RELEASE Award of options by Chief Executive Officer over personally owned shares to Chief Financial Officer and General Counsel London UK 30 November 2016: Ergomed plc ("Ergomed" or the "Company", LSE: ERGO), a pharmaceutical services and drug developm...

Acquisition of PharmInvent

RNS Number: 3466Q Ergomed plc 29 November 2016 PRESS RELEASE FOR IMMEDIATE RELEASE Ergomed strengthens PrimeVigilance with acquisition of European pharmacovigilance and regulatory services business, PharmInvent Complements existing PrimeVigilance services, consolidating market leading position and boosting sources of future growth Ex...

Ergomed chairman to step down

Ergomed chairman Rolf Stahel will retire from the board at the end of his three year term of office on 31 March and wil...

Proposed Board Changes

RNS Number: 6527P Ergomed plc 21 November 2016 PRESS RELEASE FOR IMMEDIATE RELEASE Proposed Board changes London, UK - 21 November 2016: The Board of Ergomed plc ("Ergomed" or the "Company"), announces that Rolf Stahel, who has served as Chairman since April 2014, has indicated that he will retire from the Board at the expiry of his th...

Ergomed expands clinical study with Modus Therapeutics

Ergomed has noted that its co-development partner Modus Therapeutics Holding AB has announced that following a plan...

Research Update from Modus Therapeutics

RNS Number: 2688P Ergomed plc 16 November 2016 Ergomed's co-development partner Modus Therapeutics announces that the Independent Data Safety Monitoring Board endorses inclusion of adolescents into the Phase II clinical study with sevuparin in Sickle Cell Disease London, UK - 16 November 2016: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a c...

Holding(s) in Company

RNS Number: 2602P Ergomed plc 15 November 2016 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Ergomed Plc Ord GBP 0.01 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights An acqu...

Fundamental DataMore

P/E ratio30
EPS5.4
Dividend yield0 %

Equity Research (ERGO)

equity development
Ergomed Plc
15/12/2016
Ergomed offers clinical trial and pharmacovigilance services to pharmaceutical companies, while also co-developing a product portfolio of therapies. It has unusually high revenue visibility, indeed...
equity development
Ergomed Plc
11/10/2016
Ergomed offers clinical trial and pharmacovigilance services to pharmaceutical companies, while also co-developing a product portfolio of therapies. It has unusually high revenue visibility, indeed...

Latest discussion posts More

  • Webinar with management

    We will be hosting a webinar with the management of Ergomed tomorrow (Tuesday 27th September) at 11.15. There will be a presentation of the interim results lasting around ...
    26-Sep-2016
    equity_dev

Users' HoldingsMore

Users who hold Ergomed also hold..
SOMERO ENTER DI33%
REV BARS22%
LAKEHOUSE22%
GVC HLDGS22%
GALLIFORD TRY22%

Codes & Symbols

ISINGB00BN7ZCY67
SymbolsERGO, LSE:ERGO, ERGO.L, ERGO:LN, LON:ERGO, XLON:ERGO